AlloVir, Inc. (NASDAQ:ALVR) Sees Significant Growth in Short Interest

AlloVir, Inc. (NASDAQ:ALVRGet Rating) was the recipient of a large increase in short interest during the month of April. As of April 30th, there was short interest totalling 6,610,000 shares, an increase of 68.6% from the April 15th total of 3,920,000 shares. Based on an average daily volume of 1,710,000 shares, the days-to-cover ratio is presently 3.9 days.

In other news, insider Beek Jeroen B. Van sold 15,322 shares of the firm’s stock in a transaction on Wednesday, February 16th. The stock was sold at an average price of $8.32, for a total transaction of $127,479.04. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director David Hallal sold 40,481 shares of the firm’s stock in a transaction on Thursday, March 10th. The shares were sold at an average price of $7.55, for a total value of $305,631.55. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 61,468 shares of company stock valued at $467,529. Insiders own 54.22% of the company’s stock.

Hedge funds and other institutional investors have recently modified their holdings of the business. Invesco Ltd. bought a new stake in shares of AlloVir during the 2nd quarter valued at about $286,000. Wells Fargo & Company MN boosted its position in shares of AlloVir by 95,566.7% during the 2nd quarter. Wells Fargo & Company MN now owns 17,220 shares of the company’s stock valued at $340,000 after acquiring an additional 17,202 shares during the last quarter. SG Americas Securities LLC boosted its position in shares of AlloVir by 34.3% during the 3rd quarter. SG Americas Securities LLC now owns 15,251 shares of the company’s stock valued at $382,000 after acquiring an additional 3,897 shares during the last quarter. Deutsche Bank AG boosted its position in shares of AlloVir by 12.3% during the 3rd quarter. Deutsche Bank AG now owns 27,916 shares of the company’s stock valued at $700,000 after acquiring an additional 3,050 shares during the last quarter. Finally, BlackRock Inc. boosted its position in shares of AlloVir by 3.8% during the 3rd quarter. BlackRock Inc. now owns 1,813,179 shares of the company’s stock valued at $45,438,000 after acquiring an additional 65,695 shares during the last quarter. Institutional investors and hedge funds own 38.73% of the company’s stock.

Shares of NASDAQ ALVR opened at $4.24 on Friday. AlloVir has a 52 week low of $3.21 and a 52 week high of $26.41. The business has a 50-day simple moving average of $6.22 and a two-hundred day simple moving average of $11.15.

AlloVir (NASDAQ:ALVRGet Rating) last issued its earnings results on Thursday, May 5th. The company reported ($0.69) EPS for the quarter, topping the consensus estimate of ($0.74) by $0.05. On average, equities analysts forecast that AlloVir will post -2.81 earnings per share for the current fiscal year.

Several equities research analysts recently weighed in on ALVR shares. BMO Capital Markets started coverage on AlloVir in a report on Tuesday, February 1st. They issued an “outperform” rating and a $130.00 price objective for the company. Zacks Investment Research lowered AlloVir from a “hold” rating to a “sell” rating in a report on Monday, May 9th. SVB Leerink decreased their price objective on AlloVir from $32.00 to $30.00 and set an “outperform” rating for the company in a report on Thursday, February 10th. Finally, Morgan Stanley decreased their price objective on AlloVir from $48.00 to $45.00 and set an “overweight” rating for the company in a report on Tuesday, January 18th.

About AlloVir (Get Rating)

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus.

See Also

Receive News & Ratings for AlloVir Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AlloVir and related companies with MarketBeat.com's FREE daily email newsletter.